-
Psychedelic Research Expands In Australia With Palliative Care Partnership & New MDMA Analog Portfolio
Tuesday, March 21, 2023 - 3:52pm | 546Psyence Partners with iNGENū for Palliative Care Clinical Trial Life sciences biotech company Psyence Group Inc (OTCQB: PSYGF)’s wholly-owned Australian subsidiary Psyence Australia Pty Ltd. partnered with Contract Research Organization (CRO) iNGENū Pty Ltd to conduct a Phase 2b clinical...
-
Novel Ketamine Topical Cream To Treat PTSD Gets First In-Human Trials
Thursday, February 16, 2023 - 2:11pm | 517Psycheceutical Bioscience (OTCPK: BWVI) is advancing its proprietary ketamine topical formulation into clinical studies. The life sciences company has partnered with Australian-based contract research organization iNGENū Pty Ltd. The exclusive agreement is set to design and conduct two Phase...
-
Psychedelics Funding At Its Best: $1.5M Destined To Psilocin Clinical Trials In Australia
Thursday, September 1, 2022 - 2:20pm | 503Psychedelics biopharma company Lobe Sciences Ltd. (OTCQB: LOBEF) signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 million for an annual term with a 15% interest. Funding for...
-
Lobe Sciences Signs Exclusive Deal For Psilocin Clinical Trials In Australia
Wednesday, August 10, 2022 - 1:31pm | 379Life sciences company Lobe Sciences Ltd. (OTCQB: LOBEF) and Australian contract research organization iNGENū Pty Ltd. have agreed to design and conduct three or more clinical studies testing Lobe's psilocin analogs, L-130 or L-131, under exclusive terms. iNGENū works on a global scale,...
-
Tetra Bio-Pharma And Cannvalate Enter Into Partnership
Thursday, May 5, 2022 - 10:55am | 587Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) has entered into a research and development agreement with Cannvalate Pty Ltd for the initiation of the REBORN, PLENITUDE and CAUMZ clinical trials in Australia, and a subscription agreement contemplating a private placement of common shares...